Who's in the Driver's Seat? IgAN vs. FSGS as Competing Drivers of Progressive CKD in the Setting of a Variant of Uncertain Significance (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0548; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Discussion If IgAN is driving increasing proteinuria and progression of CKD, new therapies should be considered, including sparsentan for CKD attenuation, and upstream agents, including iptacopan, sibeprenlimab, atacicept or targeted release budesonide, to reduce proteinuria to the new goal of < 0.3-0.5g/day. Shared decision-making should be employed in cases with two pathologic diagnoses on renal biopsy, with a possible time-limited trial of treatment for IgAN to assess response. The appropriate use of new disease-altering therapies for IgAN, a relatively common second, and sometimes incidental, finding on biopsy, should be investigated further to better predict who should receive these medications."
Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Human Immunodeficiency Virus • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • CD2AP
|
|
Prasiddha Senthil Kumar; Suzanne Gwen Martin
|